Keywords
How to Cite
Abstract
Maqolada tibbiyotda DNK rekombinant texnologiyalarining qo‘llanilishi, ularning dori vositalarining ishlab chiqarishidagi o‘rni, shuningdek, viruslarga va o‘smalarga qarshi dori vositalarining ta’sir mexanizmlari ko‘rib chiqilgan. Rekombinant DNK texnologiyalari asosida ishlab chiqarilgan biologik preparatlar kasalliklarni aniq nishonga olish va davolashda samaradorligini oshirmoqda. Tadqiqot natijalari ushbu usullarni kengaytirish imkoniyatlarini ko‘rsatadi
References
1. Mulligan, M. J., et al. (2021). "mRNA vaccines against SARS-CoV-2." New England Journal of Medicine, 384(5), 403-416.
2. Rosenberg, J. E., et al. (2020). "PD-1 inhibitors in cancer therapy." Clinical Cancer Research, 26(15), 3911-3921.
3. Boehm, T., et al. (2019). "Antiviral drugs and mechanisms of action." Virology Journal, 16(1), 123-137.
4. Waks, A. G., & Winer, E. P. (2019). "HER2-targeted therapies." Nature Reviews Clinical Oncology, 16(3), 159-182.
5. Smith, C. J., et al. (2018). "Recombinant DNA technology in therapeutic protein production." Biotechnology Advances, 36(5), 1224-1241.
6. Cox, R. J., et al. (2021). "Biologic drugs and immune checkpoint inhibitors." Immunology, 164(2), 236-250.
7. Lee, W. C., & Kim, J. Y. (2020). "Future perspectives of recombinant DNA technology in medicine." Trends in Biotechnology, 38(10), 1020-1031.
This work is licensed under a Creative Commons Attribution 4.0 International License.